June 23 in Chicago. At American Diabetes Association Should help to create a buzz as all trials should be completed by then. Title: A Phase 1, Open-Label, Randomized Dose Proportionality Study of Technosphere® Insulin Inhalation Powder (TI) Doses up to 80 U Administered with the Gen2 Inhaler in Healthy Subjects http://www.abstractsonline.com/Plan/SSResults.aspx